SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-023838
Filing Date
2024-03-01
Accepted
2024-03-01 16:05:20
Documents
17
Period of Report
2024-02-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vktx-20240228.htm   iXBRL 8-K 56541
2 EX-1.1 vktx-ex1_1.htm EX-1.1 320125
3 EX-5.1 vktx-ex5_1.htm EX-5.1 13700
4 EX-99.1 vktx-ex99_1.htm EX-99.1 19628
5 GRAPHIC img201808844_0.jpg GRAPHIC 11467
6 GRAPHIC img246856755_0.jpg GRAPHIC 5653
  Complete submission text file 0000950170-24-023838.txt   619159

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vktx-20240228.xsd EX-101.SCH 30714
18 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20240228_htm.xml XML 4720
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

IRS No.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37355 | Film No.: 24709566
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)